Introduction
Materials and methods
Patient selection
Tissue microarray
Immunohistochemistry (IHC)
Antibody | Clone | Dilution | Source |
---|---|---|---|
Molecular subtype related
| |||
ER | SP1 | 1:100 | Thermo Scientific, CA, USA |
PR | PgR | 1:50 | DAKO, Denmark |
HER-2 | Polyclonal | 1:1500 | DAKO, Denmark |
Ki-67 | MIB-1 | 1:150 | DAKO, Denmark |
Glycolysis related
| |||
Glut-1 | SPM498 | 1:200 | Abcam, Cambridge, UK |
Hexokinase II | 3D3 | 1:200 | Abcam, Cambridge, UK |
CAIX | Polyclonal | 1:100 | Abcam, Cambridge, UK |
MCT4 | Polyclonal | 1:100 | Santa Cruz, CA, USA |
Glutaminolysis related
| |||
GLS1 | Polyclonal | 1:50 | Abcam, Cambridge, UK |
GDH | Polyclonal | 1:100 | Abcam, Cambridge, UK |
ASCT2 | Polyclonal | 1:100 | Abcam, Cambridge, UK |
Mitochondrial related
| |||
ATP synthase | 15H4C4 | 1:100 | Abcam, Cambridge, UK |
SDHA | 2E3GC12FB2AE2 | 1:100 | Abcam, Cambridge, UK |
SDHB | 21A11AE7 | 1:100 | Abcam, Cambridge, UK |
Serine/glycine metabolism related
| |||
PHGDH | Polyclonal | 1:100 | Abcam, Cambridge, UK |
PSPH | Polyclonal | 1:100 | Abcam, Cambridge, UK |
PSAT1 | Polyclonal | 1:100 | Abcam, Cambridge, UK |
SHMT | Polyclonal | 1:100 | Abcam, Cambridge, UK |
GLDC | Polyclonal | 1:100 | Abcam, Cambridge, UK |
Interpretation of immunohistochemical results
Tumor phenotype classification
Classification of tumor metabolic subtype
Statistical analysis
Results
Baseline characteristics of patients
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
---|---|---|---|---|---|---|
Age (yr, mean ± SD) | 52.0 ± 10.5 | 52.3 ± 10.0 | 53.5 ± 11.7 | 54.2 ± 10.8 | 49.7 ± 9.5 | 0.221 |
ER |
<0.001
| |||||
Negative | 69 (42.6) | 8 (17.0) | 26 (66.7) | 6 (25.0) | 29 (55.8) | |
Positive | 93 (57.4) | 39 (83.0) | 13 (33.3) | 18 (75.0) | 23 (44.2) | |
PR |
<0.001
| |||||
Negative | 109 (67.3) | 23 (48.9) | 38 (97.4) | 12 (50.0) | 36 (69.2) | |
Positive | 53 (32.7) | 24 (51.1) | 1 (2.6) | 12 (50.0) | 16 (30.8) | |
HER-2 |
0.017
| |||||
Negative | 114 (70.4) | 38 (80.9) | 20 (51.3) | 19 (79.2) | 37 (71.2) | |
Positive | 48 (29.6) | 9 (19.1) | 19 (48.7) | 5 (20.8) | 15 (28.8) | |
Molecular subtypes |
<0.001
| |||||
Luminal A | 67 (41.4) | 33 (70.2) | 4 (10.3) | 15 (62.5) | 15 (28.8) | |
Luminal B | 27 (16.7) | 7 (14.9) | 9 (23.1) | 3 (12.5) | 8 (15.4) | |
HER-2 | 30 (18.5) | 5 (10.6) | 12 (30.8) | 3 (12.5) | 10 (19.2) | |
TNBC | 38 (23.5) | 2 (4.3) | 14 (35.9) | 3 (12.5) | 19 (36.5) | |
Time to metastasis (month, mean ± SD) | 30.3 ± 38.0 | 29.3 ± 29.2 | 32.7 ± 32.6 | 18.2 ± 16.8 | 35.1 ± 38.0 | 0.182 |
Patients death | 53 (32.7) | 23 (48.9) | 11 (28.2) | 7 (29.2) | 12 (23.1) |
0.040
|
Expression of metabolism-related proteins in breast cancer metastasis according to metastatic site (Figure 1)
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
---|---|---|---|---|---|---|
Glut-1 |
<0.001
| |||||
Negative | 83 (51.2) | 35 (74.5) | 10 (25.6) | 18 (75.0) | 20 (38.5) | |
Positive | 79 (48.8) | 12 (25.5) | 29 (74.4) | 6 (25.0) | 32 (61.5) | |
Hexokinase II |
0.001
| |||||
Negative | 113 (69.8) | 41 (87.2) | 25 (64.1) | 20 (83.3) | 27 (51.9) | |
Positive | 49 (30.2) | 6 (12.8) | 14 (35.9) | 4 (16.7) | 25 (48.1) | |
CAIX |
0.009
| |||||
Negative | 130 (80.2) | 44 (93.6) | 26 (66.7) | 21 (87.5) | 39 (75.0) | |
Positive | 32 (19.8) | 3 (6.4) | 13 (33.3) | 3 (12.5) | 13 (25.0) | |
MCT4 |
<0.001
| |||||
Negative | 66 (40.7) | 25 (53.2) | 4 (10.3) | 13 (54.2) | 24 (46.2) | |
Positive | 96 (59.3) | 22 (46.8) | 35 (89.7) | 11 (45.8) | 28 (53.8) | |
GLS1 | 0.473 | |||||
Negative | 83 (51.2) | 28 (59.6) | 17 (43.6) | 11 (45.8) | 27 (51.9) | |
Positive | 79 (48.8) | 19 (40.4) | 22 (56.4) | 13 (54.2) | 25 (48.1) | |
GDH | 0.610 | |||||
Negative | 2 (1.2) | 1 (2.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) | |
Positive | 160 (98.8) | 46 (97.9) | 38 (97.4) | 24 (100.0) | 52 (100.0) | |
ASCT2 |
0.033
| |||||
Negative | 122 (75.3) | 37 (78.7) | 34 (87.2) | 19 (79.2) | 32 (61.5) | |
Positive | 40 (24.7) | 10 (21.3) | 5 (12.8) | 5 (20.8) | 20 (38.5) | |
ATP synthase | 0.610 | |||||
Negative | 2 (1.2) | 1 (2.1) | 1 (2.6) | 0 (0.0) | 0 (0.0) | |
Positive | 160 (98.8) | 46 (97.9) | 38 (97.4) | 24 (100.0) | 52 (100.0) | |
SDHA | 0.175 | |||||
Negative | 2 (1.2) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Positive | 160 (98.8) | 45 (95.7) | 39 (100.0) | 24 (100.0) | 52 (100.0) | |
SDHB |
0.006
| |||||
Negative | 52 (32.1) | 20 (42.6) | 16 (41.0) | 9 (37.5) | 7 (13.5) | |
Positive | 110 (67.9) | 27 (57.4) | 23 (59.0) | 15 (62.5) | 45 (86.5) | |
PHGDH |
0.027
| |||||
Negative | 61 (37.7) | 24 (51.1) | 11 (28.2) | 12 (50.0) | 14 (26.9) | |
Positive | 101 (62.3) | 23 (48.9) | 28 (71.8) | 12 (50.0) | 38 (73.1) | |
PSPH | 0.926 | |||||
Negative | 146 (90.1) | 42 (89.4) | 36 (92.3) | 22 (91.7) | 46 (88.5) | |
Positive | 16 (9.9) | 5 (10.6) | 3 (7.7) | 2 (8.3) | 6 (11.5) | |
PSAT1 |
<0.001
| |||||
Negative | 140 (86.4) | 41 (87.2) | 37 (94.9) | 14 (58.3) | 48 (92.3) | |
Positive | 22 (13.6) | 6 (12.8) | 2 (5.1) | 10 (41.7) | 4 (7.7) | |
SHMT1 |
0.033
| |||||
Negative | 127 (78.4) | 43 (91.5) | 31 (79.5) | 18 (75.0) | 35 (67.3) | |
Positive | 35 (21.6) | 4 (8.5) | 8 (20.5) | 6 (25.0) | 17 (32.7) | |
GLDC | 0.547 | |||||
Negative | 96 (59.3) | 31 (66.0) | 24 (61.5) | 14 (58.3) | 27 (51.9) | |
Positive | 66 (40.7) | 16 (34.0) | 15 (38.5) | 10 (41.7) | 25 (48.1) |
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
---|---|---|---|---|---|---|
Hexokinase II | 0.058 | |||||
Negative | 159 (98.1) | 44 (93.6) | 39 (100.0) | 24 (100.0) | 52 (100.0) | |
Positive | 3 (1.9) | 3 (6.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
MCT4 |
0.002
| |||||
Negative | 113 (69.8) | 26 (55.3) | 36 (92.3) | 17 (70.8) | 34 (65.4) | |
Positive | 49 (30.2) | 21 (44.7) | 3 (7.7) | 7 (29.2) | 18 (34.6) | |
GLS1 |
0.006
| |||||
Negative | 157 (96.9) | 42 (89.4) | 39 (100.0) | 24 (100.0) | 52 (100.0) | |
Positive | 5 (3.1) | 5 (10.6) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
GDH |
0.035
| |||||
Negative | 140 (86.4) | 36 (76.6) | 38 (97.4) | 22 (91.7) | 44 (84.6) | |
Positive | 22 (13.6) | 11 (23.4) | 1 (2.6) | 2 (8.3) | 8 (15.4) | |
ATP synthase | 0.084 | |||||
Negative | 155 (95.7) | 42 (89.4) | 38 (97.4) | 24 (100.0) | 51 (98.1) | |
Positive | 7 (4.3) | 5 (10.6) | 1 (2.6) | 0 (0.0) | 1 (1.9) | |
SDHA |
0.004
| |||||
Negative | 145 (89.5) | 36 (76.6) | 38 (97.4) | 21 (87.5) | 50 (96.2) | |
Positive | 17 (10.5) | 11 (23.4) | 1 (2.6) | 3 (12.5) | 2 (3.8) | |
PHGDH |
0.018
| |||||
Negative | 158 (97.5) | 43 (91.5) | 39 (100.0) | 24 (100.0) | 52 (100.0) | |
Positive | 4 (2.5) | 4 (8.5) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
PSPH |
0.006
| |||||
Negative | 156 (96.3) | 46 (97.9) | 34 (87.2) | 24 (100.0) | 52 (100.0) | |
Positive | 6 (3.7) | 1 (2.1) | 5 (12.8) | 0 (0.0) | 0 (0.0) | |
PSAT1 |
<0.001
| |||||
Negative | 154 (95.1) | 46 (97.9) | 32 (82.1) | 24 (100.0) | 52 (100.0) | |
Positive | 8 (4.9) | 1 (2.1) | 7 (17.9) | 0 (0.0) | 0 (0.0) | |
SHMT1 |
<0.001
| |||||
Negative | 98 (60.5) | 16 (34.0) | 31 (79.5) | 16 (66.7) | 35 (67.3) | |
Positive | 64 (39.5) | 31 (66.0) | 8 (20.5) | 8 (33.3) | 17 (32.7) |
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | p-value |
---|---|---|---|---|---|---|
Glycolysis type |
<0.001
| |||||
No | 81 (50.0) | 36 (76.6) | 9 (23.1) | 17 (70.8) | 19 (36.5) | |
Yes | 81 (50.0) | 11 (23.4) | 30 (76.9) | 7 (29.2) | 33 (63.5) | |
Glutamine type | 0.308 | |||||
No | 62 (38.4) | 23 (48.9) | 14 (35.9) | 9 (37.5) | 16 (30.8) | |
Yes | 100 (61.7) | 24 (51.1) | 25 (64.1) | 15 (62.5) | 36 (69.2) | |
Mitochondrial type | 0.175 | |||||
No | 2 (1.2) | 2 (4.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
Yes | 160 (98.8) | 45 (95.7) | 39 (100.0) | 24 (100.0) | 52 (100.0) | |
Serine/glycine type | 0.444 | |||||
No | 128 (79.0) | 37 (78.7) | 34 (87.2) | 19 (79.2) | 38 (73.1) | |
Yes | 34 (21.0) | 10 (21.3) | 5 (12.8) | 5 (20.8) | 14 (26.9) |
Correlation of expression of metabolism-related proteins between primary and metastatic breast cancer according to metastatic site
Parameters | Total | Bone metastasis | Brain metastasis | Liver metastasis | Lung metastasis | |||||
---|---|---|---|---|---|---|---|---|---|---|
N = 49 (%) | p-value | n = 13 (%) | p-value | n = 9 (%) | p-value | n = 4 (%) | p-value | n = 23 (%) | p-value | |
Glut-1 | 0.481 | 0.063 | 1.000 | 1.000 |
0.004
| |||||
(+) → (+) | 10 (20.4) | 0 (0.0) | 4 (44.4) | 0 (0.0) | 6 (20.4) | |||||
(+) → (−) | 7 (14.3) | 5 (38.5) | 1 (11.1) | 1 (25.0) | 0 (0.0) | |||||
(−) → (+) | 11 (22.4) | 0 (0.0) | 2 (22.2) | 0 (0.0) | 9 (39.1) | |||||
(−) → (−) | 21 (42.9) | 8 (61.5) | 2 (22.2) | 3 (75.0) | 8 (34.8) | |||||
Hexokinase II | 0.581 | 1.000 | 0.500 | 1.000 | 1.000 | |||||
(+) → (+) | 11 (22.4) | 1 (7.7) | 1 (11.1) | 0 (0.0) | 9 (39.1) | |||||
(+) → (−) | 5 (10.2) | 3 (23.1) | 0 (0.0) | 0 (0.0) | 2 (8.7) | |||||
(−) → (+) | 8 (16.3) | 2 (15.4) | 2 (22.2) | 1 (25.0) | 3 (13.0) | |||||
(−) → (−) | 25 (51.0) | 7 (53.8) | 6 (66.7) | 3 (75.0) | 9 (39.1) | |||||
CAIX | 0.688 | N/A | 1.000 | N/A | 1.000 | |||||
(+) → (+) | 2 (4.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (8.7) | |||||
(+) → (−) | 2 (4.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 1 (4.3) | |||||
(−) → (+) | 4 (8.2) | 0 (0.0) | 2 (22.2) | 0 (0.0) | 2 (8.7) | |||||
(−) → (−) | 41 (83.7) | 13 (100.0) | 6 (66.7) | 4 (100.0) | 18 (78.3) | |||||
MCT4 |
0.002
| 0.250 | 0.250 | 0.500 |
0.004
| |||||
(+) → (+) | 14 (28.6) | 3 (23.1) | 4 (44.4) | 0 (0.0) | 7 (30.4) | |||||
(+) → (−) | 2 (4.1) | 0 (0.0) | 0 (0.0) | 2 (50.0) | 0 (0.0) | |||||
(−) → (+) | 15 (30.6) | 3 (23.1) | 3 (33.3) | 0 (0.0) | 9 (39.1) | |||||
(−) → (−) | 18 (36.7) | 7 (53.8) | 2 (22.2) | 2 (50.0) | 7 (30.4) | |||||
GLS1 | 1.000 | 0.063 | 1.000 | 1.000 | 0.289 | |||||
(+) → (+) | 15 (30.6) | 2 (15.4) | 3 (33.3) | 2 (50.0) | 8 (34.8) | |||||
(+) → (−) | 8 (16.3) | 0 (0.0) | 1 (11.1) | 1 (25.0) | 6 (26.1) | |||||
(−) → (+) | 9 (18.4) | 5 (38.5) | 2 (22.2) | 0 (0.0) | 2 (8.7) | |||||
(−) → (−) | 17 (34.7) | 6 (46.2) | 3 (33.3) | 1 (25.0) | 7 (30.4) | |||||
GDH | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 | |||||
(+) → (+) | 44 (89.8) | 11 (84.6) | 8 (88.9) | 3 (75.0) | 22 (95.7) | |||||
(+) → (−) | 2 (4.1) | 1 (7.7) | 1 (11.1) | 0 (0.0) | 0 (0.0) | |||||
(−) → (+) | 3 (6.1) | 1 (7.7) | 0 (0.0) | 1 (25.0) | 1 (4.3) | |||||
(−) → (−) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
ASCT2 | 0.092 | 1.000 | 0.219 | 1.000 | 0.375 | |||||
(+) → (+) | 8 (16.3) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 7 (30.4) | |||||
(+) → (−) | 10 (20.4) | 1 (7.7) | 5 (55.6) | 0 (0.0) | 4 (17.4) | |||||
(−) → (+) | 3 (6.1) | 1 (7.7) | 1 (11.1) | 0 (0.0) | 1 (4.3) | |||||
(−) → (−) | 28 (57.1) | 11 (84.6) | 3 (33.3) | 3 (75.0) | 11 (47.8) | |||||
ATP synthase | 1.000 | 1.000 | N/A | N/A | N/A | |||||
(+) → (+) | 48 (98.0) | 12 (92.3) | 9 (100.0) | 4 (100.0) | 23 (100.0) | |||||
(+) → (−) | 1 (2.0) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
(−) → (+) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
(−) → (−) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
SDHA | 1.000 | 1.000 | 1.000 | N/A | N/A | |||||
(+) → (+) | 44 (89.8) | 9 (69.2) | 8 (88.9) | 4 (100.0) | 23 (100.0) | |||||
(+) → (−) | 2 (4.1) | 2 (15.4) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
(−) → (+) | 3 (6.1) | 2 (15.4) | 1 (11.1) | 0 (0.0) | 0 (0.0) | |||||
(−) → (−) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |||||
SDHB | 0.263 | 1.000 | 1.000 | 1.000 | 0.063 | |||||
(+) → (+) | 24 (49.0) | 4 (30.8) | 3 (33.3) | 1 (25.0) | 16 (69.9) | |||||
(+) → (−) | 7 (14.3) | 3 (23.1) | 3 (33.3) | 1 (25.0) | 0 (0.0) | |||||
(−) → (+) | 13 (26.5) | 3 (23.1) | 3 (33.3) | 2 (50.0) | 5 (21.7) | |||||
(−) → (−) | 5 (10.2) | 3 (23.1) | 0 (0.0) | 0 (0.0) | 2 (8.7) | |||||
PHGDH | 0.581 | 1.000 | 1.000 | 1.000 | 0.688 | |||||
(+) → (+) | 22 (44.9) | 3 (23.1) | 6 (66.7) | 1 (25.0) | 12 (52.2) | |||||
(+) → (−) | 5 (10.2) | 2 (15.4) | 1 (11.1) | 0 (0.0) | 2 (8.7) | |||||
(−) → (+) | 8 (16.3) | 2 (15.4) | 1 (11.1) | 1 (25.0) | 4 (17.4) | |||||
(−) → (−) | 14 (28.6) | 6 (46.2) | 1 (11.1) | 2 (50.0) | 5 (21.7) | |||||
PSPH | 1.000 | N/A | 1.000 | 1.000 | 1.000 | |||||
(+) → (+) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.3) | |||||
(+) → (−) | 3 (6.1) | 0 (0.0) | 1 (11.1) | 0 (0.0) | 2 (8.7) | |||||
(−) → (+) | 2 (4.1) | 0 (0.0) | 0 (0.0) | 1 (25.0) | 1 (4.3) | |||||
(−) → (−) | 43 (87.8) | 13 (100.0) | 8 (88.9) | 3 (75.0) | 19 (82.6) | |||||
PSAT1 | 0.607 | 1.000 | 1.000 | 1.000 | 0.219 | |||||
(+) → (+) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.3) | |||||
(+) → (−) | 9 (18.4) | 3 (23.1) | 0 (0.0) | 1 (25.0) | 5 (21.7) | |||||
(−) → (+) | 6 (12.2) | 2 (15.4) | 1 (11.1) | 2 (50.0) | 1 (4.3) | |||||
(−) → (−) | 33 (67.3) | 8 (61.5) | 8 (88.9) | 1 (25.0) | 16 (69.6) | |||||
SHMT1 | 1.000 | 1.000 | 1.000 | N/A | 1.000 | |||||
(+) → (+) | 10 (20.4) | 0 (0.0) | 2 (22.2) | 0 (0.0) | 8 (34.8) | |||||
(+) → (−) | 2 (4.1) | 1 (7.7) | 0 (0.0) | 0 (0.0) | 1 (4.3) | |||||
(−) → (+) | 1 (2.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (4.3) | |||||
(−) → (−) | 36 (73.5) | 12 (92.3) | 7 (77.8) | 4 (100.0) | 13 (56.5) | |||||
GLDC | 0.143 | 0.375 | 1.000 | 1.000 | 0.508 | |||||
(+) → (+) | 12 (24.5) | 0 (0.0) | 3 (33.3) | 1 (25.0) | 8 (34.8) | |||||
(+) → (−) | 5 (10.2) | 1 (7.7) | 1 (11.1) | 0 (0.0) | 3 (13.0) | |||||
(−) → (+) | 12 (24.5) | 4 (30.8) | 1 (11.1) | 1 (25.0) | 6 (26.1) | |||||
(−) → (−) | 20 (40.8) | 8 (61.5) | 4 (44.4) | 2 (50.0) | 6 (26.1) |
Correlation between pathologic factors and expression of metabolism-related proteins
The association between the expression of metabolism-related proteins and patient prognosis
Parameters | Total N = 162 (%) | Bone metastasis n = 47 (%) | Brain metastasis n = 39 (%) | Liver metastasis n = 24 (%) | Lung metastasis n = 52 (%) | |||||
---|---|---|---|---|---|---|---|---|---|---|
Mean survival (95% CI) months |
P-value | Mean survival (95% CI) months |
P-value | Mean survival (95% CI) months |
P-value | Mean survival (95% CI) months |
P-value | Mean survival (95% CI) months |
P-value | |
Glut-1 | 0.141 |
0.020
| 0.504 | 0.591 | 0.833 | |||||
Negative | 121 (103–139) | 102 (76–129) | 94 (65–123) | 84 (64–105) | 131 (97–165) | |||||
Positive | 92 (72–111) | 56 (41–70) | 101 (74–127) | 62 (35–88) | 120 (89–150) | |||||
Hexokinase II | 0.727 | 0.912 | 0.680 | 0.418 | 0.192 | |||||
Negative | 112 (96–128) | 83 (61–104) | 103 (76–130) | 85 (65–105) | 146 (117–175) | |||||
Positive | 96 (68–124) | 62 (42–81) | 54 (42–65) | 56 (21–90) | 103 (69–137) | |||||
CAIX |
0.044
|
<0.001
| 0.527 | 0.964 |
0.046
| |||||
Negative | 115 (100–130) | 87 (67–108) | 115 (90–141) | 81 (61–101) | 140 (114–166) | |||||
Positive | 80 (56–103) | 16 (0–41) | 64 (42–86) | 67 (30–105) | 87 (49–124) | |||||
MCT4 | 0.612 | 0.787 | 0.995 | 0.652 | 0.456 | |||||
Negative | 107 (87–128) | 92 (62–122) | 73 (29–117) | 85 (63–107) | 120 (85–154) | |||||
Positive | 113 (95–131) | 66 (55–77) | 107 (84–130) | 61 (40–82) | 138 (107–168) | |||||
GLS1 | 0.274 | 0.690 | 0.061 | 0.348 | 0.896 | |||||
Negative | 114 (96–132) | 85 (61–108) | 133 (108–158) | 70 (52–88) | 127 (95–160) | |||||
Positive | 110 (91–130) | 61 (43–78) | 61 (43–80) | 72 (47–98) | 133 (102–164) | |||||
GDH | 0.919 | 0.171 | n/a | n/a | n/a | |||||
Negative | 165 (165–165) | 165 (165–165) | n/a | n/a | n/a | |||||
Positive | 111 (97–125) | 72 (58–86) | n/a | n/a | n/a | |||||
ASCT2 | 0.686 | 0.948 | n/a | 0.761 | 0.730 | |||||
Negative | 111 (96–127) | 89 (64–114) | n/a | 83 (62–104) | 135 (107–162) | |||||
Positive | 89 (74–104) | 80 (47–114) | n/a | 58 (40–76) | 70 (57–83) | |||||
ATP synthase | 0.965 | 0.171 | n/a | n/a | n/a | |||||
Negative | 165 (165–165) | 165 (165–165) | n/a | n/a | n/a | |||||
Positive | 111 (97–125) | 72 (58–86) | n/a | n/a | n/a | |||||
SDHA | 0.830 | 0.132 | n/a | n/a | n/a | |||||
Negative | 165 (165–165) | 165 (165–165) | n/a | n/a | n/a | |||||
Positive | 111 (96–125) | 72 (57–86) | n/a | n/a | n/a | |||||
SDHB | 0.460 | 0.630 | 0.372 | 0.870 | 0.649 | |||||
Negative | 102 (80–124) | 85 (52–118) | 115 (85–146) | 49 (45–53) | 82 (48–115) | |||||
Positive | 117 (101–133) | 68 (57–80) | 70 (52–88) | 80 (57–103) | 135 (112–158) | |||||
PHGDH | 0.590 | 0.494 | 0.878 |
0.048
| 0.939 | |||||
Negative | 117 (96–138) | 90 (61–119) | 84 (53–115) | 78 (65–90) | 127 (80–174) | |||||
Positive | 108 (90–126) | 60 (48–71) | 107 (81–133) | 64 (39–89) | 122 (89–154) | |||||
PSPH |
0.045
|
0.011
| 0.714 | 0.654 | 0.477 | |||||
Negative | 114 (99–128) | 88 (67–110) | 108 (86–131) | 83 (63–102) | 131 (105–157) | |||||
Positive | 68 (36–100) | 35 (22–49) | 30 (17–42) | 53 (22–83) | 94 (41–147) | |||||
PSAT1 | 0.542 | n/a | n/a | 0.927 | 0.074 | |||||
Negative | 109 (94–123) | n/a | n/a | 83 (59–106) | 134 (109–158) | |||||
Positive | 79 (63–95) | n/a | n/a | 65 (46–83) | 38 (11–65) | |||||
SHMT1 |
0.002
| 0.258 |
0.022
| 0.089 |
0.009
| |||||
Negative | 119 (104–134) | 84 (64–105) | 117 (95–140) | 90 (71–109) | 147 (121–172) | |||||
Positive | 63 (31–94) | 31 (7–56) | 27 (19–34) | 39 (24–55) | 78 (32–123) | |||||
GLDC | 0.281 | 0.485 |
0.024
| 0.281 | 0.370 | |||||
Negative | 115 (98–133) | 80 (55–104) | 127 (105–150) | 89 (68–111) | 135 (102–168) | |||||
Positive | 99 (80–119) | 66 (56–76) | 53 (31–76) | 59 (35–82) | 111 (78–144) | |||||
Glycolysis type | 0.615 | 0.159 | 0.614 | 0.921 | 0.961 | |||||
No | 116 (97–134) | 96 (71–122) | 91 (59–123) | 82 (61–103) | 128 (91–164) | |||||
Yes | 99 (80–118) | 63 (51–75) | 102 (76–128) | 69 (44–94) | 123 (95–151) | |||||
Glutamine type | 0.116 | 0.661 | 0.251 | 0.213 | 0.454 | |||||
No | 121 (101–142) | 90 (59–120) | 128 (96–159) | 74 (54–93) | 140 (105–175) | |||||
Yes | 99 (79–119) | 72 (51–93) | 68 (51–84) | 72 (49–95) | 129 (101–157) | |||||
Mitochondrial type | 0.830 | 0.132 | n/a | n/a | n/a | |||||
No | 165 (165–165) | 165 (165–165) | n/a | n/a | n/a | |||||
Yes | 111 (96–125) | 72 (57–86) | n/a | n/a | n/a | |||||
Serine/glycine type |
0.041
| 0.886 | 0.467 |
0.034
|
0.019
| |||||
No | 116 (101–131) | 83 (61–105) | 109 (86–133) | 90 (72–109) | 142 (116–168) | |||||
Yes | 79 (56–103) | 60 (45–76) | 66 (30–103) | 38 (15–60) | 72 (32–112) | |||||
Molecular subtypes |
0.002
|
<0.001
| 0.081 | N/A | N/A | |||||
Luminal A | 105 (86–124) | 84 (62–107) | 55 (10–100) | N/A | N/A | |||||
Luminal B | 140 (111–170) | 60 (26–93) | 138 (112–164) | N/A | N/A | |||||
HER-2 | 134 (109–158) | 62 (47–77) | 79 (60–97) | N/A | N/A | |||||
TNBC | 51 (38–64) | 3 (2–4) | 31 (22–39) | N/A | N/A |
Parameters | Overall survival | ||
---|---|---|---|
Hazard ratio | 95% CI |
P-value | |
ER status | 0.067 | ||
Negative versus positive | 10.42 | 0.846-128.4 | |
PR status | 0.091 | ||
Negative versus positive | 1.195 | 0.898-4.237 | |
HER2 status | 0.408 | ||
Negative versus positive | 0.436 | 0.075-2.869 | |
Ki-67 LI |
0.002
| ||
≤14 versus >14 | 4.096 | 1.664-10.08 | |
Tumor phenotypes | 0.147 | ||
Luminal A | |||
Luminal B | 6.697 | 0.387-116.0 | |
HER2 | 7.286 | 0.348-152.4 | |
TNBC | 0.433 | 0.055-3.387 | |
CAIX | 0.189 | ||
Negative versus positive | 1.690 | 0.773-3.695 | |
PSPH | 0.117 | ||
Negative versus positive | 2.156 | 0.825-5.634 | |
SHMT1 |
0.014
| ||
Negative versus positive | 2.836 | 1.239-6.495 | |
Serine/glycine type | 0.451 | ||
No versus Yes | 0.723 | 0.311-1.679 |